{
    "clinical_study": {
        "@rank": "60225", 
        "arm_group": {
            "arm_group_label": "Ramucirumab", 
            "arm_group_type": "Experimental", 
            "description": "Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram [mg/kg] up to 10 mg/kg) every 2\u20103 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met."
        }, 
        "brief_summary": {
            "textblock": "This trial is testing ramucirumab (LY3009806) administered to Chinese participants with\n      advanced solid tumors that are resistant to standard therapy or for whom no standard therapy\n      is available. The purpose of this study is to evaluate how safe ramucirumab is and whether\n      it causes any side effects. The study will also measure how much ramucirumab gets into the\n      blood stream and how long it takes the body to get rid of it."
        }, 
        "brief_title": "A Study in Participants With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chinese participants with histopathologically or cytologically diagnosed  advanced\n             solid tumor\n\n          -  Did not respond to standard therapy or no standard therapy is available\n\n          -  Measurable or nonmeasurable disease according to the Response Evaluation Criteria In\n             Solid Tumors (RECIST)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 at study\n             entry\n\n          -  Able to provide written informed consent\n\n          -  A life expectancy of >3 months\n\n          -  Adequate hematologic function, as defined by: Absolute neutrophil count (ANC) \u22651500\n             per cubic millimeter (mm^3); hemoglobin concentration \u22659 grams per deciliter (g/dL);\n             and platelet count \u2265100,000/mm^3\n\n          -  Adequate hepatic function, as defined by: Total bilirubin level \u22641.5 x the upper\n             limit of normal (ULN) (in participants with known Gilbert Syndrome, a total bilirubin\n             \u2264 3.0 x ULN with direct bilirubin \u2264 1.5 x ULN); aspartate aminotransferase (AST) and\n             alanine aminotransferase (ALT) \u22642.5 x ULN (or \u22645 x ULN if the participant has liver\n             metastases\n\n          -  Adequate renal function, as defined by: Serum creatinine level \u22641.5 x ULN; or\n             calculated serum creatinine clearance (Cockcroft-Gault) \u226550 milliliters per minute\n             (mL/min)\n\n          -  Urinary protein is 0 or 1+ on dipstick but no edema nor serum albumin < lower level\n             of normal\n\n          -  Adequate coagulation function, as defined by: International normalized ratio (INR)\n             \u22641.5, or prothrombin time (PT) \u22641.5 x ULN and activated partial thromboplastin time\n             (aPTT) \u22641.5 x ULN (unless receiving anticoagulation therapy)\n\n          -  Agrees to use adequate contraception during the study period and for 12 weeks after\n             the last dose of study treatment\n\n        Exclusion Criteria:\n\n          -  Had chemotherapy or therapeutic radiotherapy within 14 days (6 weeks for nitrosoureas\n             or mitomycin C) before entering the study or the participant has ongoing side effects\n             (\u2265 Grade 2) due to previously administered agents\n\n          -  Has obvious evidence of intratumor cavitation\n\n          -  Has undergone major surgery within 28 days before study entry or has had a central\n             venous access device inserted within 7 days before study entry\n\n          -  Has a history of gastrointestinal perforation, postoperative bleeding complications,\n             or wound complications from a surgical procedure\n\n          -  Has elective or planned surgery to be conducted during the trial\n\n          -  Has documented and/or symptomatic brain or leptomeningeal metastases\n\n          -  Has uncontrolled ongoing illness, for example: thrombotic or hemorrhagic disorders;\n             hemoptysis; ongoing infection requiring systemic antibiotic treatment; congestive\n             heart failure, angina pectoris, angioplasty, stenting, or myocardial infarction\n             within 6 months; stroke, transient ischemic attack (TIA), or other grade 3-4 arterial\n             thromboembolic event occurring within 6 months; uncontrolled hypertension (\u2265150/\u226590\n             millimeters of mercury [mmHg]); cardiac arrhythmia that requires treatment or\n             asymptomatic sustained ventricular tachycardia; peripheral neuropathy \u2265Grade 2; human\n             immunodeficiency virus (HIV) or active, uncontrolled hepatitis, liver cirrhosis at a\n             level of Child-Pugh Class B (or worse), liver cirrhosis (any degree) and a history of\n             hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis.\n             (Clinically meaningful ascites is defined as ascites resulting from cirrhosis and\n             requiring ongoing treatment with diuretics and/or paracentesis)\n\n          -  Has a serious or nonhealing wound, ulcer, or bone fracture within 28 days before\n             study entry\n\n          -  Has experienced any Grade 3 or 4 gastrointestinal bleeding within 3 months before\n             study entry\n\n          -  Has a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal\n             abscess <6 months before randomization, or the participant has a history of poorly\n             controlled or recurrent inflammatory bowel disease (including Crohn's disease or\n             ulcerative colitis)\n\n          -  Has participated in a clinical study of a non-approved experimental agent or\n             procedure within 4 weeks prior to study entry for small molecules, or 8 weeks before\n             study entry for nonapproved monoclonal antibodies\n\n          -  Has a known allergy to ramucirumab or its excipients, a monoclonal antibody (MAb), or\n             any other therapeutic protein, such as fresh frozen plasma, human serum albumin\n             (HSA), cytokines, or interleukins. If there is suspicion that the participant may\n             have an allergy, the participant should be excluded\n\n          -  Is pregnant (confirmed by urine or serum pregnancy test) or lactating\n\n          -  Has known alcohol or drug dependency\n\n          -  Is receiving chronic therapy with nonsteroidal anti-inflammatory agents (NSAIDs)\n\n          -  Is not considered to be suitable for this study, in the opinion of the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682135", 
            "org_study_id": "14139", 
            "secondary_id": "I4T-CR-JVBU"
        }, 
        "intervention": {
            "arm_group_label": "Ramucirumab", 
            "description": "Administered IV.", 
            "intervention_name": "Ramucirumab", 
            "intervention_type": "Biological", 
            "other_name": [
                "IMC-1121B", 
                "LY3009806"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200032"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of Ramucirumab in Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559)", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants with One or More Drug-Related Adverse Events (AEs) or Any Serious AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through study completion (estimated as 32 months)"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) and Minimum Concentration (Cmin) of Ramucirumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Cycle 5, Day 1"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of Ramucirumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Cycle 5, Day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682135"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Response to disease progression or death (estimated as 10 weeks)"
            }, 
            {
                "measure": "Duration of Stable Disease", 
                "safety_issue": "No", 
                "time_frame": "Baseline to disease progression (estimated as 10 weeks)"
            }, 
            {
                "measure": "Time to Disease Progression", 
                "safety_issue": "No", 
                "time_frame": "Baseline to disease progression (estimated as 10 weeks)"
            }, 
            {
                "measure": "Number of Participants with Anti-Ramucirumab Antibodies", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Cycle 3, Day 1"
            }, 
            {
                "measure": "Percentage of Participants with Best Objective Response (BOR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to measured response (estimated as 10 weeks)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}